Isis's mipomersen passes second Phase III trial, but safety concerns spook investors
11 February 2010
Asher Mullard
Please Login to read the full article.
11 February 2010
Asher Mullard
asher.mullard@informa.com
Isis Pharmaceuticals' mipomersen – a first-in-class lipid-lowering antisense therapy – has passed its second Phase III trial, reducing LDL-cholesterol (LDL-C) levels significantly in patients with heterozygous familial hypercholesterolaemia (heFH). Although the positive results mark...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Aegerion expects to file in US, Europe by year end for lomitapide for rare lipid disorder
- Genzyme and Isis report updated mipomersen results, as firms prepare for filings
- FDA panel backs Merck's Vytorin in predialysis CKD, but rejects dialysis use
- Familial cholesterol tests from Gen-Probe, Progenika fall short of NICE expectations
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
